Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s Half Trillion Dollar Economic Stimulus Plan To Boost Healthcare Sector

This article was originally published in PharmAsia News

Executive Summary

BEIJING - China's new plan to inject RMB 4 trillion into the economy to stimulate growth and counter the effects of the global financial crisis will boost the overall health care sector and propel medical system reforms, according to analysts

You may also be interested in...



China's Top Medical Device Maker Says Beijing's Health Reforms Boosted Earnings, But U.S. Outlook Still Uncertain

BEIJING - The leadership at China's top medical device developer, Mindray Medical International, said this week that the launch of Beijing's health system reforms and massive hospital building program had helped boost profits in the second quarter despite a spending freeze imposed by some medical centers in Mindray's second-largest market, in the U.S

China's Top Medical Device Maker Says Beijing's Health Reforms Boosted Earnings, But U.S. Outlook Still Uncertain

BEIJING - The leadership at China's top medical device developer, Mindray Medical International, said this week that the launch of Beijing's health system reforms and massive hospital building program had helped boost profits in the second quarter despite a spending freeze imposed by some medical centers in Mindray's second-largest market, in the U.S

Biopharma Industry Slated As China Pillar Industry, But Key Domestic Support Missing

SHANGHAI - Biopharmaceuticals will take a share in the Chinese central government's RMB 62.8 billion ($9.18 billion) investment plan to facilitate 11 key projects during 2009 to 2010. China's State Council passed a policy in May to promote the biotech industry to develop it as one of China's pillar industries in the future

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC067161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel